
CLAIMS

1. Use of a~~A~~ thienopyridone derivative compound of Formula (I):



(I)

wherein:

R1 represents a hydrogen atom or a halogen atom,

R2 represents an indanyl or tetralinyl group, substituted or not by one or more groups selected from halogen atoms, alkyl groups, hydroxy, alkoxy groups, amino, mono- or di-alkylamino groups, carboxy groups, alkyloxycarbonyl groups, mono- or di-alkylaminocarbonyl groups, carboxamide, cyano, alkylsulfonyl and trifluoromethyl groups,

R3 represents an aryl group, substituted or not by one or more atoms or groups selected from halogen atoms, alkyl groups, hydroxy, alkoxy groups, aralkyloxy groups, amino, mono- or di-alkylamino groups, carboxy groups, alkyloxycarbonyl groups, mono- or di-alkylaminocarbonyl groups, carboxamide, cyano, alkylsulfonyl and trifluoromethyl groups,

or its pharmaceutically acceptable salts and/or solvates,

~~or a pharmaceutical composition comprising the same,~~

in the preparation of a medicament ~~for use~~ in the treatment of autosomal dominant polycystic kidney disease (ADPKD).

2. The use according to claim 1, wherein the thienopyridone derivative compound ~~of claim 1 or a pharmaceutical composition comprising the same for use according to claim 1, wherein said compound~~ is to be administered once or twice a day at a daily dose of 0.5mg to 3000 mg for a human patient.

3. The use according to claim 2, wherein the thienopyridone derivative compound is to be administered once or twice a day at a daily dose of~~preferably from~~ 20 mg to 1000 mg.

4. The use according to claim 2, wherein the thienopyridone derivative compound is to be administered once or twice a day at a daily dose of~~, more preferably from~~ 60 mg to 500 mg.

~~3~~5. The ~~thienopyridone derivative of claim 1 or a pharmaceutical composition comprising the same for~~ use according to any one of claims 1 to 4~~or 2~~, wherein said thienopyridone derivative compound ~~or pharmaceutical composition~~ is effective for preventing or limiting cyst growth or reducing cyst volume.

~~4~~6. The ~~thienopyridone derivative of claim 1 for~~ use according to any one of claims 1 to ~~3~~5, wherein at least one of the following conditions is met and preferably all of them:

- R1 represents a halogen atom~~, in particular a chlorine atom~~,
- R2 is unsubstituted or substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is a tetralinyl group,
- R3 represents a phenyl group, which is unsubstituted or substituted by 1 or 2 substituents,
- the compound of formula (I) is in the form of a salt~~, preferably a sodium or potassium salt, more preferably a potassium salt~~,
- the compound of formula (I) is in the form of a solvate~~, preferably a hydrate, more preferably a monohydrate~~.

~~5~~7. The ~~thienopyridone derivative of claim 4 for~~ use according to any one of claims 1 to ~~3~~5, wherein at least one of the following conditions is met and preferably all of them:

- R1 represents a halogen atom~~, in particular a chlorine atom~~,
- R2 is substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is a tetralinyl group,
- R3 represents a phenyl group, which is unsubstituted,
- the compound of formula (I) is in the form of a salt~~, preferably a sodium or potassium salt, more preferably a potassium salt~~,
- the compound of formula (I) is in the form of a solvate~~, preferably a hydrate, more preferably a monohydrate~~.

8. The use according to claims 1 to 7, wherein R1 represents a chlorine atom.


9. The use according to any one of claims 1 to 8, wherein the compound of formula (I) is in the form of a sodium or potassium salt.

10. The use according to any one of claims 1 to 9, wherein the compound of formula (I) is in the form of a solvate and it is a hydrate.

11. The use according to claim 10, wherein the compound of formula (I) is a monohydrate.

12. The use according to any one of claims 1 to 11, wherein the thienopyridone derivative compound is 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-oner, or a pharmaceutically acceptable salt or solvate thereof.

~~6~~13. The ~~thienopyridone derivative of claim 5 for~~ use according to any one of claims 1 to ~~3~~ 12 ~~which~~ wherein the thienopyridone derivative compound is the monohydrate potassium salt of 2-chloro-4-hydroxy-3-(5-hydroxytetralin-6-yl)-5-phenyl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ia):




(Ia)

~~7~~14. The ~~thienopyridone derivative of claim 1 for~~ use according to any one of claims 1 to 5 ~~3~~, wherein at least one of, or all of ,the following conditions is met ~~and preferably all of them~~:

- R1 represents a halogen atom, ~~in particular a chlorine atom,~~
- R2 is substituted by 1 or 2 substituents including at least one hydroxy group,
- R2 is an indanyl group,


- R3 represents a phenyl group, which is unsubstituted or substituted by 1 or 2 substituents.

~~8~~15. The ~~thienopyridone derivative of claim 7 for~~ use according to any one of claims 1 to ~~3~~ 5 and 14, wherein the thienopyridone derivative ~~which~~ is the 2-chloro-5-(4-fluorophenyl)-4-hydroxy-3-indan-5-yl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ib):



(Ib)

~~9~~16. The ~~thienopyridone derivative of claim 7 for~~ use according to any one of claims 1 to ~~3~~ 5 and 14, wherein the thienopyridone derivative ~~which~~ is the 2-chloro-4-hydroxy-3-indan-5-yl-5-phenyl-7H-thieno[2,3-b]pyridin-6-one having Formula (Ic):



(Ic)

17. The use according to any one of claims 1 to 5, wherein thienopyridone derivative compound of formula (I) is such that:

R1 is Cl,

R2 is an indanyl or tetralinyl group optionally substituted by a hydroxy group, and

R3 is a phenyl group optionally substituted with a halogen,

or a pharmaceutically acceptable salt or solvate thereof.